This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings.
Study Type
OBSERVATIONAL
Enrollment
8,125
Observational study on treatment satisfaction of Levemir ® versus Protaphane® during "real-life" usage in Germany
Observational study on treatment satisfaction of Levemir ® versus Protaphane® during "real-life" usage in Germany
Novo Nordisk Investigational Site
Mainz, Germany
treatment satisfaction (DTSQs and DTSQc)
Time frame: over whole study duration, 24 weeks per patient
diabetes-related quality of life (ADDQoL)
Time frame: over whole study duration, 24 weeks per patient
general health-related quality of life (EQ-5D)
Time frame: over whole study duration, 24 weeks per patient
Body weight
Time frame: over whole study duration, 24 weeks per patient
metabolic control (HbA1c, fasting morning blood glucose)
Time frame: over whole study duration, 24 weeks per patient
Insulin dose
Time frame: over whole study duration, 24 weeks per patient
concomitant diabetes therapy (OADs)
Time frame: over whole study duration, 24 weeks per patient
Hypoglycemia
Time frame: over whole study duration, 24 weeks per patient
Adverse drug reactions, ADR
Time frame: over whole study duration, 24 weeks per patient
Serious adverse drug reactions, SADR
Time frame: over whole study duration, 24 weeks per patient
Pregnancy
Time frame: over whole study duration, 24 weeks per patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.